Impel Pharmaceuticals Inc

+0.32 (+5.14%)
Earnings Announcements

Impel Neuropharma Reports Q4 Non-GAAP Loss Per Share $1.07

Published: 03/24/2022 12:36 GMT
Impel Pharmaceuticals Inc (IMPL) - Impel Neuropharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update.
Q4 Non-GAAP Loss per Share $1.07.
Impel Neuropharma - Co Projects That Trudhesa Will Deliver Prescriptions Within Range of 70,000 - 85,000 for FY 2022.
Believes, Based on Its Current Operating Plan, That It Has Sufficient Capital to Fund Operations Into 2024.
Revenue is expected to be $3.84 Million
Adjusted EPS is expected to be -$1.05

Next Quarter Revenue Guidance is expected to be $8.09 Million
Next Quarter EPS Guidance is expected to be -$0.95

More details on our Analysts Page.